
Joel W Neal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8674590/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer, 2022, 23, e148-e153.	1.1	16
2	Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer, 2022, 23, 264-272.	1.1	11
3	Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer, 2022, 23, e210-e221.	1.1	11
4	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 2022, 30, 100497.	0.7	4
5	Abstract PO-130: Disparities in risk of second primary lung cancer among lung cancer patients in the United States. , 2022, , .		0
6	Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 295-306.	1.3	16
7	ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer, 2022, 166, 112-125.	1.3	4
8	The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. Journal of the National Cancer Institute, 2022, 114, 618-625.	3.0	13
9	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Drugs, 2022, 82, 649-662.	4.9	15
10	Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer, 2022, 23, 498-509.	1.1	1
11	EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2022, 40, TPS9146-TPS9146.	0.8	3
12	PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer, 2021, 22, e329-e335.	1.1	4
13	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology, 2021, 61, 113-134.	4.2	40
14	Opportunistic Invasive Fungal Infections Mimicking Progression of Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e193-e200.	1.1	12
15	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry, 2021, 67, 534-542.	1.5	14
16	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discovery, 2021, 11, 1688-1699.	7.7	154
17	Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors. JACC: CardioOncology, 2021, 3, 137-139.	1.7	55
18	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	6.6	80

#	Article	IF	CITATIONS
19	Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncology Practice, 2021, 17, e1688-e1697.	1.4	7
20	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer, 2021, 22, 201-209.	1.1	24
21	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology, 2021, 16, 868-872.	0.5	42
22	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, 1030-1041.	0.5	79
23	Radiological tumour classification across imaging modality and histology. Nature Machine Intelligence, 2021, 3, 787-798.	8.3	41
24	Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non–Small-Cell Lung Cancer. JCO Oncology Practice, 2021, 17, e1131-e1138.	1.4	1
25	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. Journal of Thoracic Oncology, 2021, 16, 2029-2039.	0.5	34
26	The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 4864-4871.	0.6	3
27	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology, 2021, 16, 1479-1489.	0.5	2
28	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of <i>KRAS</i> -Mutated Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 153-162.	1.5	4
29	Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1994-1998.	0.5	7
30	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 274-281.	3.2	75
31	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. Cancer Discovery, 2020, 10, 1826-1841.	7.7	93
32	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
33	A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications, 2020, 23, 100174.	0.7	10
34	Integrating genomic features for non-invasive early lung cancer detection. Nature, 2020, 580, 245-251.	13.7	379
35	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 2020, 1, 176-183.	5.7	201
36	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74

#	Article	IF	CITATIONS
37	Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study Journal of Clinical Oncology, 2020, 38, 9610-9610.	0.8	25
38	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer, 2019, 133, 144-150.	0.9	90
39	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer, 2019, 134, 42-45.	0.9	37
40	Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor–Induced Pneumonitis. Journal of Thoracic Oncology, 2019, 14, e75-e77.	0.5	2
41	Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor–Related Papulopustular Eruption. JAMA Dermatology, 2019, 155, 848.	2.0	4
42	<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 2019, 37, 278-285.	0.8	286
43	Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes― Lung Cancer, 2019, 137, 159-160.	0.9	2
44	Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, e21-e24.	0.5	23
45	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non–small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e208-e217.	1.1	9
46	Osimertinib for <i>EGFR</i> -Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. Oncologist, 2019, 24, 836-843.	1.9	34
47	Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research, 2018, 24, 2771-2779.	3.2	141
48	Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2677-2679.	0.8	8
49	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non–Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, 2018, 4, 1-9.	0.5	3
50	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non–Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2018, 2, 1-13.	1.5	8
51	Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e581-e588.	1.1	22
52	Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. Lung Cancer, 2018, 122, 187-191.	0.9	5
53	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
54	ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology, 2017, 12, 833-842.	0.5	86

#	Article	IF	CITATIONS
55	Elusive Target of Angiogenesis in Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 1269-1271.	0.8	5
56	The persistent promise of combining HGF/MET and EGFR inhibition in nonâ€small cell lung cancer. Cancer, 2017, 123, 2798-2801.	2.0	2
57	Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Molecular Diagnosis and Therapy, 2017, 21, 431-436.	1.6	2
58	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 338-343.	0.3	29
59	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discovery, 2017, 7, 1394-1403.	7.7	701
60	Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, 16-21.	0.4	14
61	Novel systemic therapy against malignant pleural mesothelioma. Translational Lung Cancer Research, 2017, 6, 295-314.	1.3	22
62	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, e8-e15.	1.8	13
63	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics, 2016, 38, 1567-1576.	1.1	11
64	Molecular profiling of single circulating tumor cells from lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8379-E8386.	3.3	90
65	Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice, 2016, 12, 763-764.	2.5	1
66	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2016, 17, 1661-1671.	5.1	115
67	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	5.8	520
68	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	9.4	837
69	Unicentric, Multifocal Castleman Disease of the Mediastinum Associated With Cerebellitis. Annals of Thoracic Surgery, 2015, 99, e7-e9.	0.7	5
70	Developing biomarker-specific end points in lung cancer clinical trials. Nature Reviews Clinical Oncology, 2015, 12, 135-146.	12.5	43
71	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1547-1552.	3.3	115
72	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Civen for Cancer Therapy. American Journal of Ophthalmology, 2015, 160, 799-805.e1.	1.7	68

#	Article	IF	CITATIONS
73	Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction. Lung Cancer, 2015, 89, 280-286.	0.9	18
74	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer, 2015, 90, 1-7.	0.9	14
75	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 366-373.	1.1	23
76	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer, 2015, 87, 34-38.	0.9	27
77	Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational Lung Cancer Research, 2015, 4, 639-41.	1.3	16
78	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Research, 2015, 35, 669-76.	0.5	5
79	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 2014, 20, 548-554.	15.2	1,771
80	Successes, toxicities and challenges in solid tumours. Nature Reviews Clinical Oncology, 2014, 11, 627-628.	12.5	23
81	Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. Clinical Lung Cancer, 2014, 15, 202-206.	1.1	68
82	Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 576.	0.9	59
83	A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non–Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. Clinical Lung Cancer, 2013, 14, 592-595.	1.1	33
84	A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors. Cancer Discovery, 2013, 3, 1364-1377.	7.7	366
85	Aflibercept in lung cancer. Expert Opinion on Biological Therapy, 2013, 13, 115-120.	1.4	6
86	Current Management of Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 853-863.	0.8	34
87	Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. Current Treatment Options in Oncology, 2010, 11, 36-44.	1.3	48
88	The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncology, 2010, 6, 1827-1832.	1.1	19